Medicare drug coverage costs more this year

Most seniors in Medicare's prescription-drug program are paying considerably higher monthly premiums this year, according to a new study; we'll have to wait and see whether the higher costs force seniors to drop coverage--and in turn, some of their prescription drugs. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.